Search Results - "CUI, Jean"

Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress by Cui, J. Jean

“…The HGF/MET signaling pathway is critical in mediating a wide range of normal physiological functions including embryological development, wound healing, and…”
Get full text

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer by Yun, Mi Ran, Kim, Dong Hwi, Kim, Seok-Young, Joo, Hyeong-Seok, Lee, You Won, Choi, Hun Mi, Park, Chae Won, Heo, Seong Gu, Kang, Han Na, Lee, Sung Sook, Schoenfeld, Adam J, Drilon, Alexander, Kang, Seok-Gu, Shim, Hyo Sup, Hong, Min Hee, Cui, J Jean, Kim, Hye Ryun, Cho, Byoung Chul

“…Although first-line crizotinib treatment leads to clinical benefit in lung cancer, high prevalence of crizotinib-resistant ROS1-G2032R (ROS1 ) mutation and…”
Get full text

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) by Cui, J. Jean, Tran-Dubé, Michelle, Shen, Hong, Nambu, Mitchell, Kung, Pei-Pei, Pairish, Mason, Jia, Lei, Meng, Jerry, Funk, Lee, Botrous, Iriny, McTigue, Michele, Grodsky, Neil, Ryan, Kevin, Padrique, Ellen, Alton, Gordon, Timofeevski, Sergei, Yamazaki, Shinji, Li, Qiuhua, Zou, Helen, Christensen, James, Mroczkowski, Barbara, Bender, Steve, Kania, Robert S, Edwards, Martin P

“…Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncology targets for therapeutic…”
Get full text

Crizotinib for the Treatment of ALK‐Rearranged Non‐Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology by Ou, Sai‐Hong Ignatius, Bartlett, Cynthia Huang, Mino‐Kenudson, Mari, Cui, Jean, Iafrate, A. John

“…Crizotinib, an ALK/MET/ROS1 inhibitor, was approved by the U.S. Food and Drug Administration for the treatment of anaplastic lymphoma kinase (ALK)‐rearranged…”
Get full text

Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2‑(4-(1-(Quinolin-6-ylmethyl)‑1H‑[1,2,3]triazolo[4,5‑b]pyrazin-6-yl)‑1H‑pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer by Cui, J. Jean, McTigue, Michele, Nambu, Mitchell, Tran-Dubé, Michelle, Pairish, Mason, Shen, Hong, Jia, Lei, Cheng, Hengmiao, Hoffman, Jacqui, Le, Phuong, Jalaie, Mehran, Goetz, Gilles H, Ryan, Kevin, Grodsky, Neil, Deng, Ya-li, Parker, Max, Timofeevski, Sergei, Murray, Brion W, Yamazaki, Shinji, Aguirre, Shirley, Li, Qiuhua, Zou, Helen, Christensen, James

“…The c-MET receptor tyrosine kinase is an attractive oncology target because of its critical role in human oncogenesis and tumor progression. An oxindole…”
Get full text

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review by Zhu, Viola W., Nagasaka, Misako, Madison, Russell, Schrock, Alexa B., Cui, Jean, Ou, Sai-Hong Ignatius

“…Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired ALK resistance mutations, including the solvent-front mutation…”
Get full text

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis by Karachaliou, Niki, Chaib, Imane, Cardona, Andres Felipe, Berenguer, Jordi, Bracht, Jillian Wilhelmina Paulina, Yang, Jie, Cai, Xueting, Wang, Zhigang, Hu, Chunping, Drozdowskyj, Ana, Servat, Carles Codony, Servat, Jordi Codony, Ito, Masaoki, Attili, Ilaria, Aldeguer, Erika, Capitan, Ana Gimenez, Rodriguez, July, Rojas, Leonardo, Viteri, Santiago, Molina-Vila, Miguel Angel, Ou, Sai-Hong Ignatius, Okada, Morihito, Mok, Tony S, Bivona, Trever G, Ono, Mayumi, Cui, Jean, Ramón Y Cajal, Santiago, Frias, Alex, Cao, Peng, Rosell, Rafael

“…Epidermal growth factor receptor (EGFR)-mutation-positive non-smallcell lung cancer (NSCLC) is incurable, despite high rates of response to EGFR tyrosine…”
Get full text

Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase by Sun, Li, Liang, Chris, Shirazian, Sheri, Zhou, Yong, Miller, Todd, Cui, Jean, Fukuda, Juri Y, Chu, Ji-Yu, Nematalla, Asaad, Wang, Xueyan, Chen, Hui, Sistla, Anand, Luu, Tony C, Tang, Flora, Wei, James, Tang, Cho

“…To improve the antitumor properties and optimize the pharmaceutical properties including solubility and protein binding of indolin-2-ones, a number of…”
Get full text

Synthesis of Aryl Ethers via a Sulfonyl Transfer Reaction by Sach, Neal W, Richter, Daniel T, Cripps, Stephan, Tran-Dubé, Michelle, Zhu, Huichun, Huang, Buwen, Cui, Jean, Sutton, Scott C

“…A general synthesis of aryl ethers from primary and secondary alcohols and aryl mesylates is presented. The reaction proceeds via a sulfonyl-transfer…”
Get full text

Crystal Structure of the Tyrosine Kinase Domain of the Hepatocyte Growth Factor Receptor c-Met and Its Complex with the Microbial Alkaloid K-252a by Schiering, Nikolaus, Knapp, Stefan, Marconi, Marina, Flocco, Maria M., Cui, Jean, Perego, Rita, Rusconi, Luisa, Cristiani, Cinzia

“…The protooncogene c-met codes for the hepatocyte growth factor receptor tyrosine kinase. Binding of its ligand, hepatocyte growth factor/scatter factor,…”
Get full text

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib by Huang, Qinhua, Johnson, Ted W, Bailey, Simon, Brooun, Alexei, Bunker, Kevin D, Burke, Benjamin J, Collins, Michael R, Cook, Andrew S, Cui, J. Jean, Dack, Kevin N, Deal, Judith G, Deng, Ya-Li, Dinh, Dac, Engstrom, Lars D, He, Mingying, Hoffman, Jacqui, Hoffman, Robert L, Johnson, Patrick S, Kania, Robert S, Lam, Hieu, Lam, Justine L, Le, Phuong T, Li, Qiuhua, Lingardo, Laura, Liu, Wei, Lu, Melissa West, McTigue, Michele, Palmer, Cynthia L, Richardson, Paul F, Sach, Neal W, Shen, Hong, Smeal, Tod, Smith, Graham L, Stewart, Albert E, Timofeevski, Sergei, Tsaparikos, Konstantinos, Wang, Hui, Zhu, Huichun, Zhu, Jinjiang, Zou, Helen Y, Edwards, Martin P

“…Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is…”
Get full text

Abstract 2132: The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors by Zhai, Dayong, Deng, Wei, Huang, Zhongdong, Rogers, Evan, Cui, J. Jean

“…Non-small cell lung cancers harboring rearrangements involving the ALK gene are sensitive to treatment with the ALK inhibitor crizotinib. However, the…”
Get full text

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations by Johnson, Ted W, Richardson, Paul F, Bailey, Simon, Brooun, Alexei, Burke, Benjamin J, Collins, Michael R, Cui, J Jean, Deal, Judith G, Deng, Ya-Li, Dinh, Dac, Engstrom, Lars D, He, Mingying, Hoffman, Jacqui, Hoffman, Robert L, Huang, Qinhua, Kania, Robert S, Kath, John C, Lam, Hieu, Lam, Justine L, Le, Phuong T, Lingardo, Laura, Liu, Wei, McTigue, Michele, Palmer, Cynthia L, Sach, Neal W, Smeal, Tod, Smith, Graham L, Stewart, Albert E, Timofeevski, Sergei, Zhu, Huichun, Zhu, Jinjiang, Zou, Helen Y, Edwards, Martin P

“…Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung carcinoma patients, progression during…”
Get full text

Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor by Zou, Helen Y, Li, Qiuhua, Lee, Joseph H, Arango, Maria E, Burgess, Kristina, Qiu, Ming, Engstrom, Lars D, Yamazaki, Shinji, Parker, Max, Timofeevski, Sergei, Cui, Jingrong Jean, McTigue, Michele, Los, Gerrit, Bender, Steven L, Smeal, Tod, Christensen, James G

“…The c-Met pathway has been implicated in a variety of human cancers for its critical role in tumor growth, invasion, and metastasis. PF-04217903 is a novel…”
Get full text

A New Challenging and Promising Era of Tyrosine Kinase Inhibitors by Cui, J. Jean

“…Protein kinases are key regulators that govern complex cellular processes. Dysregulation of kinase signaling is associated in many human diseases, particularly…”
Get full text

Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors by Bagal, Sharan K, Omoto, Kiyoyuki, Blakemore, David C, Bungay, Peter J, Bilsland, James G, Clarke, Philip J, Corbett, Matthew S, Cronin, Ciaran N, Cui, J. Jean, Dias, Rebecca, Flanagan, Neil J, Greasley, Samantha E, Grimley, Rachel, Johnson, Eric, Fengas, David, Kitching, Linda, Kraus, Michelle L, McAlpine, Indrawan, Nagata, Asako, Waldron, Gareth J, Warmus, Joseph S

“…Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are activated by hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic…”
Get full text

High Levels of HER-2 Expression Alter the Ability of Epidermal Growth Factor Receptor (EGFR) Family Tyrosine Kinase Inhibitors to Inhibit EGFR Phosphorylation in Vivo by CHRISTENSEN, James G, SCHRECK, Randall E, MENDEL, Dirk B, CHAN, Emily, XUEYAN WANG, YANG, Chris, LUNA LIU, CUI, Jean, LI SUN, WEI, James, CHERRINGTON, Julie M

“…The epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases have been implicated in the development, progression, and severity of several human…”
Get full text

Identification of a novel T1151K ALK mutation in a patient with ALK -rearranged NSCLC with prior exposure to crizotinib and ceritinib by Zhu, Viola W, Cui, J.Jean, Fernandez-Rocha, Maria, Schrock, Alexa B, Ali, Siraj M, Ou, Sai-Hong Ignatius

“…Highlights • Novel T1151 K ALK mutation confers resistance to ceritinib. • Co-crystal structure shows a strong interaction between ceritinib and the P-loop. •…”
Get full text

Lessons from (S)‑6-(1-(6-(1-Methyl‑1H‑pyrazol-4-yl)-[1,2,4]triazolo[4,3‑b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c‑Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats by Cui, J. Jean, Shen, Hong, Tran-Dubé, Michelle, Nambu, Mitchell, McTigue, Michele, Grodsky, Neil, Ryan, Kevin, Yamazaki, Shinji, Aguirre, Shirley, Parker, Max, Li, Qiuhua, Zou, Helen, Christensen, James

“…The hepatocyte growth factor (HGF)/c-Met signaling axis is deregulated in many cancers and plays important roles in tumor invasive growth and metastasis. An…”
Get full text

Rational design of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3- d]pyrimidin-6-ones as a novel class of inhibitors of epidermal growth factor receptor (EGF-R) and Her2(p185 erbB) tyrosine kinases by Sun, Li, Cui, Jean, Liang, Congxin, Zhou, Yong, Nematalla, Asaad, Wang, Xueyan, Chen, Hui, Tang, Cho, Wei, James

“…A novel class of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3- d]pyrimidin-6-ones has been discovered as potent and selective inhibitors of the EGF-R tyrosine…”
Get full text